Journal article
National trends in the treatment of adult diffuse midline gliomas: a rare clinical scenario
Journal of neuro-oncology, v 168(2), pp 269-274
Jun 2024
PMID: 38630388
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Diffuse midline gliomas (DMG) include all midline gliomas with a point mutation to the histone H3 gene resulting in the substitution of a lysine with a methionine (K27M). These tumors are classified as World Health Organization grade 4 with a mean survival between 9- and 19-months following diagnosis. There is currently no standard of care for DMG, and palliative radiation therapy has been proven to only extend survival by months. Our current study aims to report current treatment trends and predictors of the overall survival of DMG.
We searched the National Cancer Database for adult patients treated for DMG from 2016 to 2020. Patients were required to have been treated with primary radiation directed at the brain with or without concurrent chemotherapy. Univariable and multivariable Cox regressions were used to determine predictors of overall survival.
Of the 131 patients meeting the inclusion criteria, 113 (86%) received radiation and chemotherapy. Based on multivariable Cox regression, significant predictors of survival were Charlson-Deyo comorbidity index and race. Patients with a Charlson-Deyo score of 1 had 2.72 times higher odds of mortality than those with a score of 0. Patients not identifying as White or Black had 2.67 times higher odds of mortality than those identifying as White. The median survival for all patients was 19 months.
Despite being considered ineffective, chemotherapy is still administered in most adult patients diagnosed with DMG. Significant predictors of survival were Charlson-Deyo comorbidity index and race.
Metrics
2 Record Views
Details
- Title
- National trends in the treatment of adult diffuse midline gliomas: a rare clinical scenario
- Creators
- Jay Desai - Drexel UniversitySujay Rajkumar - Drexel UniversityMatthew J Shepard - Allegheny Health NetworkJohn Herbst - Allegheny Health NetworkStephen M Karlovits - Allegheny Health NetworkShakir Hasan - New York Proton CenterZachary D Horne - Allegheny Health NetworkRodney E Wegner - Allegheny Health Network
- Publication Details
- Journal of neuro-oncology, v 168(2), pp 269-274
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurology
- Web of Science ID
- WOS:001204661200001
- Scopus ID
- 2-s2.0-85190579522
- Other Identifier
- 991022154806904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Clinical Neurology
- Oncology